You are here

P&T® Journal contents for August 2005

Features

Letter to the Editor
The debate about psychologist prescribing continues.
J. J. Rodos, DO, DSc
Successful approaches to reducing errors will require system improvements rather than exhortations for prescribers to “try harder.”
Edmond S. Weisbart, MD, and Howard E. Greenberg, MD, MSE, MBA
The authors discuss the use of rosiglitazone (Avandia®) and pioglitazone (Actos®) for patients with type-2 diabetes.
Fadia T. Shaya, PhD, MPH, Stacy Calloway, PharmD Candidate, Antoine C. El Khoury, PhD, and Josette Tomety, PharmD Candidate
The new Medicare prescription drug plan encourages beneficiaries to select generic over branded products.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Meeting Highlights
Mr. Alexander summarizes presentations on androgen-suppressing therapies for men with prostate cancer and the associated risk of osteoporosis, the use of bone scans in prostate cancer, and genetic mutations as markers for selecting pharmacotherapy.
Walter Alexander, MS
Meeting Highlights
The authors discuss therapies for asthma, chronic obstructive pulmonary disease, pulmonary hypertension, and respiratory syncytial virus disease, as well as rimonabant as an aid in smoking cessation.
Lawrence M. Prescott, PhD, and Sharon L. Prescott

Departments

Editorial
David Nash, MD, MBA, describes a White Paper about the ongoing problem of variations in health care, published by the Alliance of Community Health Plans.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses ways to prevent accidental overdoses of acetaminophen in children and how to guide parents and caregivers who administer this medication.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas explains some potential problems associated with “authorized” generic drugs, that is, new chemical equivalents of brand-name drugs that are going off their patents.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The authors review telithromycin (Ketek™) for the treatment of respiratory infections.
Amber Bell, PharmD Candidate, Marlon Honeywell, PharmD, Evans Branch III, PharmD, Patty Ghazvini, PharmD, Anya LeBron, PharmD, and Keylow King, PharmD